Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
To read the full story
Related Article
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief
February 4, 2020
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
February 1, 2019
- Oncolys Licenses Oncolytic Virus Telomelysin to Hengrui in China
December 2, 2016
BUSINESS
- KalVista Eyes Japan Debut with World’s 1st Oral On-Demand HAE Drug
March 14, 2025
- FDA Rejects Seikagaku’s Herniated Disk Drug
March 14, 2025
- Glaucoma Eye Drop Rocklatan Now Available in Singapore: Santen
March 14, 2025
- Pfizer Japan Files NDA for Tucatinib for HER2 Breast Cancer
March 14, 2025
- Mitsubishi Tanabe’s Oral Edaravone Filed in South Korea
March 14, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…